The global vaccine adjuvants market size was estimated to be USD 1.92 billion in 2023 and is expected to reach at USD 7.36 billion by 2034 with a CAGR of 12.99% during the forecast period 2024-2034. Unmet demand for specific vaccines, increasing government vaccination recommendations, increasing use of recombinant subunit and synthetic vaccines, rising cases of infectious diseases, increasing demand for vaccines, increasing government vaccination recommendations, companies are introducing new, more sophisticated vaccine adjuvants, growing research & development activities, increasing adoption of advanced technologies, and rising introduction of vaccine adjuvants are some of the key factors boosting the market growth.
Rising introduction of vaccine adjuvants is predicted to boost the market growth during the forecast period. Adjuvants are substances that boost the immune system's response to antigens, and they are incorporated into vaccines to enhance their effectiveness in providing prolonged protection against infections. Currently, the development of vaccine adjuvants is ongoing, with aluminum salts and MF59 being the only adjuvants deemed suitable for human use at present. For instance, in December 2022, Evonik has launched PhytoSquene, a squalene derived from amaranth oil that is not of animal origin and is well-suited for applications in vaccines and pharmaceuticals. Tailored for use in adjuvants in parenteral dosage forms, this product meets the demand for a dependable commercial supply of non-animal-derived squalene within the pharmaceutical sector.
By product, carbohydrate adjuvants was the highest revenue-grossing segment in the global vaccine adjuvants market in 2023 owing to its extensive applications in human vaccines, major market players are actively pursuing the development of innovative products and technologies, increase in acquisitions & partnerships with other companies, growing emphasis on the research & development of novel products. For instance, in October 2022, The initial phase of testing for a novel low-dose influenza vaccine, created as part of the INDIGO project led by AIGHD, has been completed. This innovative vaccine integrates a new adjuvant, a substance employed in various vaccines to enhance the immune response, with a licensed influenza vaccine, administered at just one-fifth of the standard dosage. Additionally, mineral salt-based adjuvant is predicted to grow at fastest CAGR during the forecast period owing to the growing trend in the utilization of mineral salt-based adjuvants, which are employed in vaccine formulations to enhance their efficacy. These mineral salts serve as adjuvants, contributing to the overall effectiveness of vaccines.
By usage, active immunostimulants was the highest revenue-grossing segment in the global vaccine adjuvants market in 2023 owing to the use of immunostimulants is on the rise, as these substances activate the body's innate immunity and encourage the production of internal immune mediators like cytokines and rising mergers & acquisitions within market players. This trend is particularly evident in the treatment of chronic infections and cancers, where immunostimulants play a vital role in bolstering the body's natural defense mechanisms. For instance, in November 2022, Hubro Therapeutics AS has acquired the GM-CSF vaccine adjuvant from Targovax ASA through an asset purchase agreement, involving a cash payment of NOK10 million. Hubro is persisting in the development of GM-CSF as an adjuvant, intending to utilize it in conjunction with its portfolio of innovative cancer vaccines. Additionally, carriers is predicted to grow at fastest CAGR during the forecast period owing to the increasing demand for vaccines and growing focus on the development of more sophisticated vaccine adjuvants.
By disease, infectious disease was the highest revenue-grossing segment in the global vaccine adjuvants market in 2023 owing to the growing prevalence of infectious diseases and increasing focus on the development of innovative medications. Additionally, cancer is predicted to grow at fastest CAGR during the forecast period owing to the rising incidences of cancer and surge in mergers & acquisitions within market players. For instance, in January 2023, Elicio Therapeutics specializes in designing adjuvants and vaccines targeted at lymph nodes for various aggressive cancers and infectious diseases. The company has entered a definitive merger agreement with Angion Biomedica Corp, emphasizing the advancement of Elicio's distinctive lymph node-targeting Amphiphile (AMP) technology for the development of immunotherapies. The primary focus is on ELI-002, a therapeutic cancer vaccine specifically designed to target mKRAS-driven tumors.
By application, research applications was the highest revenue-grossing segment in the global vaccine adjuvants market in 2023 owing to the surge in research and development (R&D) efforts directed towards creating safe and efficacious vaccines, accompanied by a notable increase in regulatory approvals. For instance, in August 2023, GSK has declared that the FDA has granted approval for Arexvy, a respiratory syncytial virus vaccine that is adjuvanted. This vaccine is designed for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals aged 60 years and older. Additionally, commercial applications is predicted to grow at fastest CAGR during the forecast period owing to the growing trend of government bodies and companies taking initiatives, coupled with an increase in the commercial utilization of various vaccine adjuvants.
North America region is anticipated for the highest revenue share during the forecast period owing to the participation of prominent industry leaders, the accessibility of advanced technology, a rise in government initiatives promoting awareness campaigns to boost vaccination rates, a growing number of product launches, collaborative agreements, numerous immunization programs, initiatives from both governmental and non-governmental entities, and an upsurge in product approvals. For instance, in November 2022, GSK plc announced that the Biologics License Application (BLA) for its respiratory syncytial virus (RSV) vaccine candidate designed for older adults has been accepted by the US FDA, and the application has been granted priority review. Priority review is bestowed upon vaccine applications by the US FDA when, if approved, they are anticipated to provide substantial enhancements in safety or effectiveness compared to standard applications for the treatment or prevention of serious conditions. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the upswing in the occurrence of infectious diseases, a heightened utilization of vaccine adjuvants, governmental recommendations & policies advocating for immunization, and growing approval of novel products. For instance, in May 2022, The National Medical Products Administration (NMPA) in China has given approval for GlaxoSmithKline's (GSK) two-dose vaccine regimen, Cervarix, designed for girls aged nine to 14 years to prevent cervical cancer. Cervarix is a recombinant, non-infectious, AS04-adjuvanted HPV bivalent vaccine, targeting types 16 and 18.
Rising introduction of vaccine adjuvants is predicted to boost the market growth during the forecast period. Adjuvants are substances that boost the immune system's response to antigens, and they are incorporated into vaccines to enhance their effectiveness in providing prolonged protection against infections. Currently, the development of vaccine adjuvants is ongoing, with aluminum salts and MF59 being the only adjuvants deemed suitable for human use at present. For instance, in December 2022, Evonik has launched PhytoSquene, a squalene derived from amaranth oil that is not of animal origin and is well-suited for applications in vaccines and pharmaceuticals. Tailored for use in adjuvants in parenteral dosage forms, this product meets the demand for a dependable commercial supply of non-animal-derived squalene within the pharmaceutical sector.
By product, carbohydrate adjuvants was the highest revenue-grossing segment in the global vaccine adjuvants market in 2023 owing to its extensive applications in human vaccines, major market players are actively pursuing the development of innovative products and technologies, increase in acquisitions & partnerships with other companies, growing emphasis on the research & development of novel products. For instance, in October 2022, The initial phase of testing for a novel low-dose influenza vaccine, created as part of the INDIGO project led by AIGHD, has been completed. This innovative vaccine integrates a new adjuvant, a substance employed in various vaccines to enhance the immune response, with a licensed influenza vaccine, administered at just one-fifth of the standard dosage. Additionally, mineral salt-based adjuvant is predicted to grow at fastest CAGR during the forecast period owing to the growing trend in the utilization of mineral salt-based adjuvants, which are employed in vaccine formulations to enhance their efficacy. These mineral salts serve as adjuvants, contributing to the overall effectiveness of vaccines.
By usage, active immunostimulants was the highest revenue-grossing segment in the global vaccine adjuvants market in 2023 owing to the use of immunostimulants is on the rise, as these substances activate the body's innate immunity and encourage the production of internal immune mediators like cytokines and rising mergers & acquisitions within market players. This trend is particularly evident in the treatment of chronic infections and cancers, where immunostimulants play a vital role in bolstering the body's natural defense mechanisms. For instance, in November 2022, Hubro Therapeutics AS has acquired the GM-CSF vaccine adjuvant from Targovax ASA through an asset purchase agreement, involving a cash payment of NOK10 million. Hubro is persisting in the development of GM-CSF as an adjuvant, intending to utilize it in conjunction with its portfolio of innovative cancer vaccines. Additionally, carriers is predicted to grow at fastest CAGR during the forecast period owing to the increasing demand for vaccines and growing focus on the development of more sophisticated vaccine adjuvants.
By disease, infectious disease was the highest revenue-grossing segment in the global vaccine adjuvants market in 2023 owing to the growing prevalence of infectious diseases and increasing focus on the development of innovative medications. Additionally, cancer is predicted to grow at fastest CAGR during the forecast period owing to the rising incidences of cancer and surge in mergers & acquisitions within market players. For instance, in January 2023, Elicio Therapeutics specializes in designing adjuvants and vaccines targeted at lymph nodes for various aggressive cancers and infectious diseases. The company has entered a definitive merger agreement with Angion Biomedica Corp, emphasizing the advancement of Elicio's distinctive lymph node-targeting Amphiphile (AMP) technology for the development of immunotherapies. The primary focus is on ELI-002, a therapeutic cancer vaccine specifically designed to target mKRAS-driven tumors.
By application, research applications was the highest revenue-grossing segment in the global vaccine adjuvants market in 2023 owing to the surge in research and development (R&D) efforts directed towards creating safe and efficacious vaccines, accompanied by a notable increase in regulatory approvals. For instance, in August 2023, GSK has declared that the FDA has granted approval for Arexvy, a respiratory syncytial virus vaccine that is adjuvanted. This vaccine is designed for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals aged 60 years and older. Additionally, commercial applications is predicted to grow at fastest CAGR during the forecast period owing to the growing trend of government bodies and companies taking initiatives, coupled with an increase in the commercial utilization of various vaccine adjuvants.
North America region is anticipated for the highest revenue share during the forecast period owing to the participation of prominent industry leaders, the accessibility of advanced technology, a rise in government initiatives promoting awareness campaigns to boost vaccination rates, a growing number of product launches, collaborative agreements, numerous immunization programs, initiatives from both governmental and non-governmental entities, and an upsurge in product approvals. For instance, in November 2022, GSK plc announced that the Biologics License Application (BLA) for its respiratory syncytial virus (RSV) vaccine candidate designed for older adults has been accepted by the US FDA, and the application has been granted priority review. Priority review is bestowed upon vaccine applications by the US FDA when, if approved, they are anticipated to provide substantial enhancements in safety or effectiveness compared to standard applications for the treatment or prevention of serious conditions. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the upswing in the occurrence of infectious diseases, a heightened utilization of vaccine adjuvants, governmental recommendations & policies advocating for immunization, and growing approval of novel products. For instance, in May 2022, The National Medical Products Administration (NMPA) in China has given approval for GlaxoSmithKline's (GSK) two-dose vaccine regimen, Cervarix, designed for girls aged nine to 14 years to prevent cervical cancer. Cervarix is a recombinant, non-infectious, AS04-adjuvanted HPV bivalent vaccine, targeting types 16 and 18.
Segmentation: Vaccine Adjuvants Market Report 2023 - 2034
Vaccine Adjuvants Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Liposome Adjuvants
- Mineral Salt-based Adjuvant
- Carbohydrate Adjuvants
- Adjuvant Emulsions
- Tensoactive Adjuvants
- Virus-like Particles (VLP)
- Bacteria-derived Adjuvants
- Others
Vaccine Adjuvants Market Analysis & Forecast by Usage 2023 - 2034 (Revenue USD Bn)
- Active Immunostimulants
- Vehicle Adjuvants
- Carriers
Vaccine Adjuvants Market Analysis & Forecast by Disease 2023 - 2034 (Revenue USD Bn)
- Cancer
- Infectious Disease
Vaccine Adjuvants Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Commercial Applications
- Research Applications
Vaccine Adjuvants Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Vaccine Adjuvants Market: Product Estimates & Trend Analysis
8. Vaccine Adjuvants Market: Usage Estimates & Trend Analysis
9. Vaccine Adjuvants Market: Disease Estimates & Trend Analysis
10. Vaccine Adjuvants Market: Application Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Vaccine Adjuvants Market
13. Europe Global Vaccine Adjuvants Market
14. Asia Pacific Global Vaccine Adjuvants Market
15. Latin America Global Vaccine Adjuvants Market
16. MEA Global Vaccine Adjuvants Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Merck & Co. Inc.
- Thermo Fisher Scientific Inc.
- Pacific GeneTech Limited
- Associated British Foods PLC (SPI Pharma Inc.)
- CSL Limited
- OZ Biosciences
- InvivoGen
- Air Liquide (Seppic)
- Dynavax Technologies Corporation
- Croda International PLC
- GlaxoSmithKline PLC
- VertellusAgenus Inc.
- Novavax Inc.
- Adjuvatis
- Aphios Corporation
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 1.92 Billion |
| Forecasted Market Value ( USD | $ 7.36 Billion |
| Compound Annual Growth Rate | 12.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
